| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
BKIDC-1553 is a multi‑targeted agent that inhibits angiotensin‑converting enzyme (ACE) and CYP2C8. ACE (peptidyl‑dipeptidase A) is a key enzyme in the renin‑angiotensin system that converts angiotensin I to the vasoconstrictor angiotensin II. CYP2C8 is a cytochrome P450 enzyme involved in drug metabolism and the metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs), which have roles in inflammation and cancer. By inhibiting ACE, BKIDC-1553 may affect tumor angiogenesis and microenvironment. By inhibiting CYP2C8, it may alter the metabolism of other drugs and endogenous lipids. BKIDC-1553 is a bumped kinase inhibitor (BKI) derivative, a class originally developed for parasitic infections but repurposed for cancer.
|
|---|---|
| ln Vitro |
BKIDC-1553 (1.25-20 μM, 72 h) inhibits cell proliferation in a dose-dependent manner in various human prostate cancer cell lines[1].
In vitro, BKIDC-1553 (1.25-20 uM; 72 hours) inhibits cell proliferation in various human prostate cancer cell lines in a dose‑dependent manner. The compound is an orally active antiglycolytic agent, suggesting that it may inhibit glycolysis, the metabolic pathway preferentially used by cancer cells (the Warburg effect). It also inhibits the enzymes CYP2C8 and angiotensin‑converting enzyme (ACE). No specific IC50 values for ACE or CYP2C8 inhibition are reported. The compound has a predicted human half‑life of approximately 17 hours, indicating favorable metabolic stability. |
| ln Vivo |
BKIDC-1553 (20 mg/kg, orally, 3 times a week for 4 weeks) reduces tumor growth in LuCaP 35 human prostate cancer patient-derived xenograft mice after 5 weeks [1].
In vivo, BKIDC-1553 (20 mg/kg; oral; three times a week; 4 weeks) reduces tumor growth in a LuCaP 35 human prostate cancer patient‑derived xenograft (PDX) mouse model at 5 weeks post‑treatment. The compound is administered orally, indicating good oral bioavailability. By inhibiting antiglycolytic activity, BKIDC-1553 disrupts the energy metabolism of cancer cells, leading to reduced tumor growth. No specific tumor growth inhibition percentages or detailed survival data are reported. |
| Enzyme Assay |
The binding of BKIDC-1553 to angiotensin‑converting enzyme (ACE) and CYP2C8 is measured by standard in vitro enzyme activity assays. For ACE inhibition, the compound is incubated with purified ACE and a fluorogenic substrate (e.g., Abz‑FRK(Dnp)‑P‑OH). The reaction is initiated, and the increase in fluorescence is measured. IC50 values are calculated from dose‑response curves. For CYP2C8 inhibition, the compound is incubated with recombinant CYP2C8 and a specific substrate (e.g., paclitaxel or amodiaquine). The formation of the metabolite is measured by LC‑MS/MS. The IC50 for CYP2C8 is calculated. No specific IC50 values are reported.
|
| Cell Assay |
For cellular assays, human prostate cancer cell lines (e.g., LNCaP, PC‑3, DU145, VCaP) are seeded in 96‑well plates (5,000-10,000 cells/well) and treated with BKIDC-1553 at concentrations of 1.25, 2.5, 5, 10, and 20 uM for 72 hours. Cell viability is measured by MTT or CellTiter‑Glo assays, and IC50 values are calculated from dose‑response curves. For mechanism studies, cells are treated with the compound and then analyzed for glycolytic flux (lactate production, glucose consumption) and ATP levels. ACE activity in cell lysates or conditioned media is measured using a fluorogenic ACE substrate.
|
| Animal Protocol |
For in vivo evaluation of antitumor activity, 6‑8‑week‑old male NOD/SCID mice are implanted subcutaneously with LuCaP 35 human prostate cancer patient‑derived xenograft (PDX) tissue fragments. When tumors reach approximately 100-150 mm3, mice are randomized (n=8-10 per group). BKIDC-1553 is administered orally by gavage at a dose of 20 mg/kg three times per week (e.g., Monday, Wednesday, Friday) for 4 weeks. Tumor volumes are measured twice weekly with calipers. Body weight is monitored as an indicator of toxicity. At the study endpoint, tumors are collected and analyzed for cell proliferation (Ki‑67 immunohistochemistry), apoptosis (cleaved caspase‑3), and glycolytic markers (lactate, pyruvate).
|
| ADME/Pharmacokinetics |
BKIDC-1553 (C22H23N5O2, MW = 389.45, purity 99.65%, CAS 1951431-34-7) is a solid powder. For storage, the powder should be kept at -20degC for up to 3 years, sealed and protected from light. For in vitro use, stock solutions in DMSO (20 mg/mL, 51.35 mM) can be stored at -80degC for up to 6 months or at -20degC for 1 month. For in vivo oral administration, it can be formulated in 10% DMSO / 40% PEG300 / 5% Tween‑80 / 45% saline or 10% DMSO / 90% corn oil. The compound is orally active, and its predicted human half‑life is approximately 17 hours. No detailed PK parameters (Cmax, Tmax, AUC) are reported.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for BKIDC-1553 are reported in the search results. The compound is noted to be an orally active antiglycolytic agent with a predicted human half‑life of 17 hours, suggesting favorable ADME properties. As a research‑grade compound, it is not intended for human or veterinary use. Standard laboratory safety precautions for handling chemicals should be followed. No LD50 or formal toxicology studies are available.
|
| References | |
| Additional Infomation |
BKIDC-1553 is a research‑grade, orally active antiglycolytic agent and bumped kinase inhibitor (BKI) derivative. BKI compounds were originally developed as inhibitors of parasite kinases (e.g., Toxoplasma gondii calcium‑dependent protein kinase 1, TgCDPK1) but have been repurposed for cancer research due to their ability to inhibit cancer cell metabolism. BKIDC-1553 has shown efficacy in prostate cancer PDX models and is a potential lead compound for the treatment of prostate cancer. The compound also inhibits CYP2C8 and ACE, which may contribute to its anticancer activity or indicate potential drug‑drug interactions. The compound is for research use only and has not entered clinical trials or received regulatory approval.
|
| Molecular Formula |
C22H23N5O2
|
|---|---|
| Molecular Weight |
389.45
|
| Exact Mass |
389.185
|
| CAS # |
1951431-34-7
|
| PubChem CID |
122442455
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
586
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(CN1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)C=C(C=C4)OC5CC5)N)O
|
| InChi Key |
NYCAEKAKFOSFFT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H23N5O2/c1-22(2,28)11-27-21-18(20(23)24-12-25-21)19(26-27)15-4-3-14-10-17(29-16-7-8-16)6-5-13(14)9-15/h3-6,9-10,12,16,28H,7-8,11H2,1-2H3,(H2,23,24,25)
|
| Chemical Name |
1-[4-amino-3-(6-cyclopropyloxynaphthalen-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]-2-methylpropan-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 20 mg/mL (51.35 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (5.14 mM)(saturation unknown) in 10% DMSO 40% PEG300 5% Tween-80 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution This solution produces a clear solution of ≥ 2 mg/mL (saturation unknown).
For example, if 1 mL of working solution, add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix well; then add 50 μL Tween-80 to the above system and mix well; then add 450 μL saline to make up to 1 mL. *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (5.14 mM)(saturation unknown) in 10% DMSO 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution This protocol will produce a clear solution of ≥ 2 mg/mL (saturation unknown). . For example, if 1 mL of working solution, add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD in saline and mix well. *Preparation of 20% SBE-β-CD saline solution (4°C, 1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formula 3: ≥ 2 mg/mL (5.14 mM)(saturation unknown) in 10% DMSO 90% Corn Oil (these co-solvents are added from left to right, one by one), clear solution This solution can obtain a clear solution of ≥ 2 mg/mL (saturation unknown). This solution can be used as appropriate for animal experiments with an experimental period of more than half a month. . For example, if you need to prepare 1 mL of working solution, add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5677 mL | 12.8386 mL | 25.6772 mL | |
| 5 mM | 0.5135 mL | 2.5677 mL | 5.1354 mL | |
| 10 mM | 0.2568 mL | 1.2839 mL | 2.5677 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
